Please login to the form below

Not currently logged in
Email:
Password:

Novartis discontinues cancer trial

Novartis has discontinued a clinical trial programme for investigational cancer treatment ASA404, incurring impairment charges of $120m

Novartis has announced it has discontinued a clinical trial programme for investigational cancer treatment ASA404 (vadimezan) after interim results from a phase III study showed the drug was unlikely to meet its primary endpoint, failing to extend patient survival.

The decision to end the programme means the Swiss company will face impairment charges of $120m to be taken in the fourth quarter of 2010. An impairment charge is a decrease in the value of a company based on inflated previous estimates regarding a company's intangible assets.

Novartis has already been hit by impairment charges in 2010, with the company facing costs of $590m when it discontinued the development of investigational compounds Mycograb (efungumab) and albinterferon alfa-2b.

Research into ASA404 was halted following a recommendation from an independent data monitoring committee to end the phase III trial, ATTRACT-2, ahead of schedule.

The trial was designed to investigate if the treatment significantly extended overall survival in patients with advanced non-small cell lung cancer (NSCLC) when used in combination with chemotherapy.

ASA404 had previously failed to meet the primary endpoint of ATTRACT-1 trial. This study evaluated the drug in combination with paclitaxel and carboplatin as first-line treatment for advanced NSCLC.

11th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics